Our study has shown that CD47 serves as a viable therapeutic target for gastric cancer, and it has also presented a potentially effective combination approach involving the inhibition of both the CD47/SIRPα axis and angiogenesis for the treatment of this disease. The gene discussed is SIRPA; the disease is gastric cancer.